glp-1 receptor agonists should be avoided in patients with GI Adverse Effects of Glucagon-Like Peptide-1 GLP1 Receptor Agonists vs SGLT2-I

As of 2015, 3.8 million people in England alone are thought to be living with the disease, according to Public Health England

C2315GS-4/SPC) using stereotaxic coordinates (0.3 mm posterior to bregma

A prespecified analysis of pooled data from the STEP-HFpEF and STEP-HFpEF DM trials demonstrated that significantly more patients treated with Wegovy 2.4 mg SC once weekly had an improvement of at least one in New York Heart Association (NYHA) functional class compared to those who received placebo (32.6% versus 21.5%, respectively

Blue Cross began covering Saxenda in 2015 when federal regulators approved it to treat weight loss, adding coverage of Wegovy in 2021 and Zepbound in 2023